Candel Therapeutics (CADL) Long-Term Debt Issuances (2022)
Candel Therapeutics (CADL) reported Long-Term Debt Issuances of $19.9 million for Q1 2022.
Candel Therapeutics (CADL) Long-Term Debt Issuances (2022) Analysis & Trends
Candel Therapeutics (CADL) has 1 years of Long-Term Debt Issuances data on file, last reported at $19.9 million in Q1 2022.
- For the quarter ending Q1 2022, Long-Term Debt Issuances changed N/A year-over-year to $19.9 million; the trailing twelve-month figure through Dec 2022 stood at $19.9 million (changed N/A YoY), and the FY2025 full-year result was $47.9 million, changed N/A from the prior year.
- Long-Term Debt Issuances was little changed at $19.9 million in Q1 2022.
- In the past five years, Long-Term Debt Issuances ranged from a high of $19.9 million in Q1 2022 to a low of $19.9 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Candel Therapeutics | 504.70 Mn | 504.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 19.91 Mn |
| Mar 31, 2022 | 19.91 Mn |